NovaBay Pharmaceuticals Inc. (NBY) Showcases 3 New Biotech Compounds at Florida Ophthalmology Conference

May 09, 2011 11:23 AM ETNBY
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Contributor Since 2008

QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net.

NovaBay Pharmaceuticals Inc., a clinical-stage biotech company developing compounds to fight bacteria, fungi and viruses, presented a poster at the 2011 Conference of the Association for Research in Vision and Ophthalmology (ARVO) held this week in Fort Lauderdale, Fla.

The poster, titled “Aganocide® Compounds Effective Against Ophthalmic Pathogens,” highlights three new Aganocide compounds similar to NovaBay’s lead anti-infective Aganocide compound, NVC-422.

Novabay’s NVC-727, NVC-638, and NVC-704 compounds are broad-spectrum, fast-acting antimicrobial agents designed with the same mechanism of action but different activity profiles.

The three new compounds expand Novabay’s current portfolio of Aganocide compounds and open a door for the company to target other medical needs.

“NVC-727, NVC-638, and NVC-704 are very exciting new molecules in our growing portfolio of broad-spectrum, fast-acting, Aganocide compounds. These compounds also provide an opportunity to treat other unmet medical needs in dermatology, urology and wound care without development of resistance,” Mark Anderson, PhD, NovaBay’s chief scientific officer, stated in the press release. “In ophthalmology, we are uniquely positioned to develop an eye drop that will treat both bacterial and viral causes of conjunctivitis including Epidemic Keratoconjunctivitis also known as EKC.”

For more information visit novabaypharma.com

Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net
 

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.